Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: Stem Cells. 2018 Feb 25;36(6):868–880. doi: 10.1002/stem.2793

A. Immunoblots and densitometric analyses of CPCs cultured under control conditions or treated with 3-Methyladenine (3-MA, 10mM, 24h). Ponceau was used to determine loading (N=4–5). B. Senescent cell counts (N=3–5). C. Immunoblots and densitometric analyses of CPCs treated with Ulk1-inhibitor SBI-0206965 (Ulk1-In, 10μM, 2h, N=4–5) D. Immunoblots and densitometric analyses of CPCs treated with BF (100nM, 4hours, N=3–6). E. Counts of cells positive for SA-β-gal (N=4–5). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N.S not significant. Data is expressed relative to control of each strain, except B. and E, where data is not normalized to control. Multiple t-tests (A, C, D), Two-way Anova (B, E).

A. Immunoblots and densitometric analyses of CPCs cultured under control conditions or treated with 3-Methyladenine (3-MA, 10mM, 24h). Ponceau was used to determine loading (N=4–5). B. Senescent cell counts (N=3–5). C. Immunoblots and densitometric analyses of CPCs treated with Ulk1-inhibitor SBI-0206965 (Ulk1-In, 10μM, 2h, N=4–5) D. Immunoblots and densitometric analyses of CPCs treated with BF (100nM, 4hours, N=3–6). E. Counts of cells positive for SA-β-gal (N=4–5). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, N.S not significant. Data is expressed relative to control of each strain, except B. and E, where data is not normalized to control. Multiple t-tests (A, C, D), Two-way Anova (B, E).